- Home
- AGAE vs LSTA Comparison
AGAE vs LSTA Comparison
Compare AGAE & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- LSTA
- Stock Information
- Founded
- AGAE 2017
- LSTA 1980
- Country
- AGAE United States
- LSTA United States
- Employees
- AGAE N/A
- LSTA N/A
- Industry
- AGAE Cable & Other Pay Television Services
- LSTA Misc Health and Biotechnology Services
- Sector
- AGAE Telecommunications
- LSTA Health Care
- Exchange
- AGAE Nasdaq
- LSTA Nasdaq
- Market Cap
- AGAE 35.0M
- LSTA 31.2M
- IPO Year
- AGAE N/A
- LSTA N/A
- Fundamental
- Price
- AGAE $0.90
- LSTA $3.71
- Analyst Decision
- AGAE
- LSTA Strong Buy
- Analyst Count
- AGAE 0
- LSTA 1
- Target Price
- AGAE N/A
- LSTA $15.00
- AVG Volume (30 Days)
- AGAE 31.1K
- LSTA 53.5K
- Earning Date
- AGAE 11-14-2024
- LSTA 02-27-2025
- Dividend Yield
- AGAE N/A
- LSTA N/A
- EPS Growth
- AGAE N/A
- LSTA N/A
- EPS
- AGAE N/A
- LSTA N/A
- Revenue
- AGAE $9,256,023.00
- LSTA N/A
- Revenue This Year
- AGAE N/A
- LSTA N/A
- Revenue Next Year
- AGAE N/A
- LSTA N/A
- P/E Ratio
- AGAE N/A
- LSTA N/A
- Revenue Growth
- AGAE 36.15
- LSTA N/A
- 52 Week Low
- AGAE $0.61
- LSTA $2.19
- 52 Week High
- AGAE $1.57
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- AGAE 52.71
- LSTA 66.07
- Support Level
- AGAE $0.89
- LSTA $3.52
- Resistance Level
- AGAE $0.93
- LSTA $3.87
- Average True Range (ATR)
- AGAE 0.07
- LSTA 0.29
- MACD
- AGAE 0.02
- LSTA 0.02
- Stochastic Oscillator
- AGAE 47.23
- LSTA 63.97
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.